Summit Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $0.0 | $0.0 | $<0.1 | $<0.1 |
| Operating income | — | -$0.2 | -$0.6 | -$0.1 | -$0.1 |
| Net income | -$1.1 | -$0.2 | -$0.6 | -$0.1 | -$0.1 |
| Cash Flow Statement | |||||
| Free cash flow | -$0.3 | -$0.1 | -$0.1 | -$<0.1 | -$0.1 |
Shares outstanding 797.7M
Annual filing data through FY ended December 31, 2025; float as of October 1, 2026.